Core Technology Laboratories, Asahi Quality & Innovations, Ltd., Midori, Moriya-shi 302-0106, Ibaraki, Japan.
Nutrients. 2022 Apr 19;14(9):1695. doi: 10.3390/nu14091695.
CP2305 (CP2305) is a paraprobiotic that exhibits beneficial effects on the intestinal function and microbiota, and increases resistance to psychological stress. The stress response mechanism mainly involves the hypothalamic-pituitary-adrenal axis, which is influenced by the gut-brain axis. Furthermore, the gut-brain axis also communicates bidirectionally with the intestinal microbiota. Additionally, the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes share a common route that affects both mental and health aspects in women. This double-blind, placebo-controlled, parallel-group clinical trial aimed to analyze the influence of the intake of CP2305 on mild symptoms associated with menopause. Eighty women aged 40-60 years ingested CP2305 or placebo tablets for six consecutive menstrual cycles. Assessment was based on the observation of climacteric symptoms with two validated questionnaires-the Simplified Menopausal Index (SMI) and the Greene Climacteric Scale (GCS). The results showed that CP2305 provided significant relief in the SMI total score, SMI vasomotor score, SMI psychological score, GCS total score, GCS somatic score, and GCS vasomotor score compared to the placebo. The percentage of women with symptom relief for the SMI total score was 75.0%, with 30 of 40 women in the CP2305 group, and 55.0%, with 22 of 40 women in the placebo group ( = 0.0594). These findings provide new insights into the function of paraprobiotic CP2305 in relieving mild climacteric symptoms in women.
CP2305(CP2305)是一种拟益生菌,对肠道功能和微生物群有有益的影响,并提高了对心理压力的抵抗力。应激反应机制主要涉及下丘脑-垂体-肾上腺轴,受肠-脑轴的影响。此外,肠-脑轴还与肠道微生物群双向通讯。此外,下丘脑-垂体-肾上腺轴和下丘脑-垂体-性腺轴共享一个共同的途径,影响女性的心理和健康方面。这项双盲、安慰剂对照、平行组临床试验旨在分析 CP2305 摄入对与绝经期相关的轻度症状的影响。80 名年龄在 40-60 岁的女性连续 6 个月经周期服用 CP2305 或安慰剂片。评估基于用两个经过验证的问卷——简化绝经期指数(SMI)和格林绝经期量表(GCS)观察绝经期症状。结果表明,CP2305 与安慰剂相比,在 SMI 总分、SMI 血管舒缩评分、SMI 心理评分、GCS 总分、GCS 躯体评分和 GCS 血管舒缩评分方面均有显著缓解。SMI 总分缓解的女性百分比为 75.0%,CP2305 组 40 名女性中有 30 名,安慰剂组为 55.0%,40 名女性中有 22 名(=0.0594)。这些发现为拟益生菌 CP2305 缓解女性轻度绝经期症状的功能提供了新的见解。